May 16 |
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
|
May 16 |
Vanda Pharmaceuticals reports positive data from motion sickness trial
|
May 15 |
Vanda reports positive Phase 3 data for motion sickness drug
|
May 15 |
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
|
May 10 |
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
|
May 9 |
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript
|
May 9 |
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
|
May 9 |
Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 9 |
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
|
May 8 |
Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M
|